Britt W, Fay J, Seals J, Kensil C
Department of Pediatrics, University of Alabama at Birmingham 35233.
J Infect Dis. 1995 Jan;171(1):18-25. doi: 10.1093/infdis/171.1.18.
The immunogenicity of a vaccine formulation consisting of recombinant-derived human cytomegalovirus (HCMV) glycoprotein B (UL55) combined with a chemically defined adjuvant derived from saponin, QS-21, was evaluated in mice. The immune responses of mice given the gB/QS-21 formulation were compared with those induced by gB combined with either Freund's adjuvant or aluminum hydroxide. The gB/QS-21 combination induced higher levels of virus-binding antibodies and significantly higher levels of virus-neutralizing antibodies than gB combined with either Freund's adjuvant or aluminum hydroxide. Animals given gB/QS-21 exhibited IgG subclass switching and produced significant titers of virus-specific IgG2a antibodies. Furthermore, animals given gB/QS-21 produced antigen-specific cytotoxic spleen cells. Because of its immunogenicity, a subunit vaccine containing HCMV gB and QS-21 offers a potential approach to the immunoprophylaxis of HCMV disease.
在小鼠中评估了由重组人巨细胞病毒（HCMV）糖蛋白B（UL55）与一种源自皂苷的化学定义佐剂QS-21组成的疫苗制剂的免疫原性。将给予gB/QS-21制剂的小鼠的免疫反应与由gB与弗氏佐剂或氢氧化铝联合诱导的免疫反应进行比较。与gB与弗氏佐剂或氢氧化铝联合相比，gB/QS-21组合诱导出更高水平的病毒结合抗体和显著更高水平的病毒中和抗体。给予gB/QS-21的动物表现出IgG亚类转换，并产生了显著滴度的病毒特异性IgG2a抗体。此外，给予gB/QS-21的动物产生了抗原特异性细胞毒性脾细胞。由于其免疫原性，含有HCMV gB和QS-21的亚单位疫苗为HCMV疾病的免疫预防提供了一种潜在方法。
